On June 2, Kelun-Biotech Biopharmaceutical fell 6.11% in regular trading, trading at 413.4 HKD/share, with trading volume of approximately 29.77 million HKD.

On the news front, reports regarding the Kelun group's across-the-board performance slowdown continued to weigh on sentiment. Kelun-Biotech posted revenue of 2.058 billion yuan for 2025, up 6.5% year-over-year, but net losses widened to 382 million yuan from 267 million yuan in the prior year, primarily due to a significant decline in licensing and milestone revenue from its Merck collaboration and elevated R&D and commercialization expenses.

Compounding the pressure, Hong Kong Stock Exchange filings revealed that Chairman Liu Gexin sold approximately 257,300 shares cumulatively between May 26 and May 28, further intensifying market concerns. The combination of widening losses across the Kelun ecosystem and insider selling triggered continued profit-taking following the stock's earlier rally driven by ASCO clinical data and analyst upgrades.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)